NeoGenomics (NASDAQ:NEO – Get Rating) and Digipath (OTCMKTS:DIGP – Get Rating) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, analyst recommendations, earnings, dividends, valuation, profitability and institutional ownership.
Institutional & Insider Ownership
88.2% of NeoGenomics shares are held by institutional investors. 1.0% of NeoGenomics shares are held by insiders. Comparatively, 10.8% of Digipath shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Risk and Volatility
NeoGenomics has a beta of 1.13, meaning that its share price is 13% more volatile than the S&P 500. Comparatively, Digipath has a beta of 1.05, meaning that its share price is 5% more volatile than the S&P 500.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares NeoGenomics and Digipath’s top-line revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|NeoGenomics||$509.73 million||4.54||-$144.25 million||($1.16)||-15.64|
|Digipath||$2.70 million||0.21||-$2.06 million||($0.02)||-0.35|
Digipath has lower revenue, but higher earnings than NeoGenomics. NeoGenomics is trading at a lower price-to-earnings ratio than Digipath, indicating that it is currently the more affordable of the two stocks.
This is a breakdown of recent recommendations and price targets for NeoGenomics and Digipath, as reported by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
NeoGenomics currently has a consensus price target of $19.33, suggesting a potential upside of 6.58%. Given NeoGenomics’ higher probable upside, equities research analysts clearly believe NeoGenomics is more favorable than Digipath.
NeoGenomics beats Digipath on 8 of the 13 factors compared between the two stocks.
NeoGenomics, Inc. is a clinical laboratory company, which engages in cancer genetics diagnostic testing and pharma services. It operates through the Clinical Services and Pharma Services segments. The Clinical Services segment offers cancer testing services to community-based pathologists, hospitals, academic centers, and oncology groups. The Pharma Services segment focuses on supporting pharmaceutical firms in drug development programs by supporting various clinical trials and research. It also provides testing services in support of its pharmaceutical clients’ oncology programs from discovery to commercialization. The company was founded by Michael T. Dent on October 29, 1998 and is headquartered in Fort Myers, FL.
DigiPath, Inc. is a service-oriented independent testing laboratory and data analytics company, which engages in the provision of cannabis testing, education, training, and news coverage. The company was founded by Todd Denkin on October 5, 2010 and is headquartered in Las Vegas, NV.
Receive News & Ratings for NeoGenomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeoGenomics and related companies with MarketBeat.com's FREE daily email newsletter.